Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.39 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.39 |
| ▸ | WNT1 | P04628 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23553687 | 0.90 | PLA2G10 (0.37) | SMN1; SMN2ALDH1A1HTTMAPTPOLB | |
| SCHEMBL572705 | 0.86 | CHRM2 (0.41) | ALDH1A1PLA2G10PLA2G5WNT1GSK3B | |
| SCHEMBL3799622 | 0.85 | PLA2G10 (0.41) | SMN1; SMN2ALDH1A1RAB9APLA2G10PLA2G5 | |
| SCHEMBL27147241 | 0.85 | PLA2G10 (0.41) | SMN1; SMN2ALDH1A1RAB9APLA2G10PLA2G5 | |
| SCHEMBL3470166 | 0.85 | PLA2G10 (0.41) | SMN1; SMN2ALDH1A1RAB9APLA2G10PLA2G5 | |
| SCHEMBL16900147 | 0.84 | WNT1 (0.38) | SMN1; SMN2PLA2G10PLA2G5WNT1GSK3B | |
| SCHEMBL14436566 | 0.84 | HSD11B1 (0.40) | SMN1; SMN2HTTPLA2G10PLA2G5WNT1 | |
| SCHEMBL18173283 | 0.83 | NR1H2 (0.43) | SMN1; SMN2ALDH1A1HTTPLA2G10PLA2G5 | |
| SCHEMBL15199143 | 0.83 | CNR1 (0.40) | ALDH1A1PLA2G10PLA2G5WNT1GSK3B | |
| SCHEMBL14971479 | 0.83 | TERT (0.39) | SMN1; SMN2ALDH1A1MAPTPLA2G10PLA2G5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4330689-A2 | CHIMERIC ABC TRANSPORTERS AND SCREENING METHODS | Genentech, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-117203529-A | Chimeric ABC transporter and screening method | 基因泰克公司 | 2023-12-08 | — | — | CN | disclosed |
| US-20230278989-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | ASTEX THERAPEUTICS LIMITED (GB) | 2023-09-07 | — | — | US | disclosed |
| US-20230278989-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | ASTEX THERAPEUTICS LIMITED (GB) | 2023-09-07 | — | — | US | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| WO-2022232125-A2 | CHIMERIC ABC TRANSPORTERS AND SCREENING METHODS | GENENTECH, INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| US-11236047-B2 | Combination of isoindolinone derivatives with SGI-110 | ASTEX THERAPEUTICS LIMITED (GB) | 2022-02-01 | — | — | US | disclosed |
| US-20210276984-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2021-09-09 | — | — | US | disclosed |
| US-10981898-B2 | Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity | ASTEX THERAPEUTICS LIMITED (GB) | 2021-04-20 | — | — | US | disclosed |
| US-20210101887-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | ASTEX THERAPEUTICS LIMITED (GB) | 2021-04-08 | — | — | US | disclosed |
| US-20200247789-A2 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUCTICS LIMITED (GB) | 2020-08-06 | — | — | US | disclosed |
| US-20200207711-A1 | COMBINATION OF ISOINDOLINONE DERIVATIVES WITH SGI-110 | ASTEX THERAPEUTICS LIMITED (GB) | 2020-07-02 | — | — | US | disclosed |
| US-10544132-B2 | Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity | ASTEX THERAPEUTICS LIMITED (GB) | 2020-01-28 | — | — | US | disclosed |
| US-20190016708-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2019-01-17 | — | — | US | disclosed |
| US-20090227620-A1 | ANTI-INFLAMMATORY COMPOUNDS | MEINGASSNER JOSEF GOTTFRIED | 2009-09-10 | — | — | US | disclosed |
| US-7482462-B2 | Acylsulfonamides as inhibitors of steroid sulfatase | NOVARTIS AG (CH) | 2009-01-27 | — | — | US | disclosed |
| US-20080293758-A1 | Combination of a Steroid Sulfatase Inhibitor and an Ascomycin | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544132-B2 | Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity | TP53, MDM2, TP53BP1 | SMN1; SMN2 3449/4885ALDH1A1 1400/4885HTT 352/4885 |
| US-20080293758-A1 | Combination of a Steroid Sulfatase Inhibitor and an Ascomycin | STS, ARSA, CYP17A1 | SMN1; SMN2 2881/4885ALDH1A1 676/4885HTT 4113/4885 |
| US-20090227620-A1 | ANTI-INFLAMMATORY COMPOUNDS | STS, SERPINB1, MPO | SMN1; SMN2 3691/4885ALDH1A1 560/4885HTT 3704/4885 |
| US-11236047-B2 | Combination of isoindolinone derivatives with SGI-110 | SGK3, SGK2, GDI2 | SMN1; SMN2 1754/4885ALDH1A1 2182/4885HTT 1374/4885 |
| US-20230278989-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | MDM2, TP53, TP53BP1 | SMN1; SMN2 4132/4885ALDH1A1 192/4885HTT 351/4885 |
| US-10981898-B2 | Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity | TP53, MDM2, TP53BP1 | SMN1; SMN2 3449/4885ALDH1A1 1400/4885HTT 352/4885 |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | SMN1; SMN2 2485/4885ALDH1A1 4385/4885HTT 895/4885 |
| US-20200207711-A1 | COMBINATION OF ISOINDOLINONE DERIVATIVES WITH SGI-110 | SGK3, SGK2, GDI2 | SMN1; SMN2 1754/4885ALDH1A1 2182/4885HTT 1374/4885 |
| US-20190016708-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | TP53, MDM2, TP53BP1 | SMN1; SMN2 3449/4885ALDH1A1 1400/4885HTT 352/4885 |
| US-20210101887-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | MDM2, TP53, TP53BP1 | SMN1; SMN2 4132/4885ALDH1A1 192/4885HTT 351/4885 |
| US-20210276984-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | TP53, MDM2, TP53BP1 | SMN1; SMN2 3449/4885ALDH1A1 1400/4885HTT 352/4885 |
| US-20200247789-A2 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | TP53, MDM2, TP53BP1 | SMN1; SMN2 3449/4885ALDH1A1 1400/4885HTT 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.